Sunshine Biopharma Inc (SBFM)

[RyGuy]

This really could be a huge winner:

Sunshine Biopharma Inc., was founded by Dr. Steve Slilaty. Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science at Cornell University and completed his Ph.D. in Molecular Biology & Biochemistry at the University of Arizona. With a passion for medicine, the doctor has founded three other biotech companies in the past and took one of them public previously. The prior company he took public was Genomics One Corporation which reached a $1 billion market cap. Dr. Slilaty is working toward the same success he had with Genomics One Corporation, in the discovery of ground breaking drugs for the treatment of aggressive forms of cancer, through Sunshine Biopharma.

Currently there are 2 genes associated with aggressive type breast cancer and they are the (HER2) and (TOP2) genes. The drug company Roche, has a drug that is called “Herceptin” that is the standard of care in HER2 positive patients, but there are currently, no therapies in production or available that target the TOP2 gene.

Enter Sunshine Biopharma, and the company’s flagship compound known as, “ Adva-27a”, that has shown tremendous results in early testing in the targeting and inhibiting of the Topoisomerase 2 (TOP2) enzyme. The technology is unique and Sunshine is the only company that has a TOP2 inhibitor along with patents covering the technology and the lead compound.

Thus far studies have shown, that Adva-27a is 16 times more effective at killing multidrug resistant breast cancer cells than Etoposide, the current chemotherapy of choice. Data also generated by the study revealed that Adva-27a is unaffected by the molecular machinery which makes cancer cells resistant to drugs, a major reason many chemotherapies fail. With this information in hand, the company has executed an agreement with The Jewish
General Hospital, one of McGill University’s Hospital Centers in Montreal, to conduct the necessary research and development to advance Sunshine’s lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials. The Phase 1 clinical trial involving 20 to 25 cancer patients, is now in the process of being completed, and the trial qualifies for “fast track” regulatory review process both in the U.S. and Canada.

If the trial is successful, Sunshine hopes to receive regulatory approval for the “compassionate use” and sale of Adva-27a for terminally ill patients. Thus allowing Sunshine Biopharma to follow in the footsteps and mimic the billion dollar cancer drug success of Roche’s drug “Herceptin”.

The company also has plans for testing the efficacy of Adva-27a in treating other TOP2 positive cancer types, such as: prostrate, colon, lung, ovarian and stomach cancers. The company notes that prostate cancer will likely be the second indication and proposed approval for the drug.